5-溴喹喔啉 | 76982-23-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 5-溴喹喔啉
• 英文名称: 5-bromoquinoxaline
• CAS: 76982-23-5
• 化学式: C₈H₅BrN₂
• 分子量: 209.045
• InChiKey: UJEGBESUCWOWNQ-UHFFFAOYSA-N

物化性质

• 沸点：
  300 °C
• 密度：
  1.656
• 闪点：
  135 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Bromoquinoxaline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromoquinoxaline
CAS number: 76982-23-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H5BrN2
Molecular weight: 209.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴喹喔啉 在 盐酸 、 tris-(dibenzylideneacetone)dipalladium(0) 、 1,2,3,4,5-五苯基-1′-(二叔丁基膦)二茂铁 、 溶剂黄146 作用下， 以 四氢呋喃 为溶剂， 生成 2-(quinoxalin-5-yl)acetic acid
  参考文献：
  名称：

  Design and synthesis of a novel, orally active, brain penetrant, tri-substituted thiophene based JNK inhibitor

  摘要：

  The SAR of a series of tri-substituted thiophene JNK3 inhibitors is described. By optimizing both the N-aryl acetamide region of the inhibitor and the 4-position of the thiophene we obtained single digit nanomolar compounds, such as 47, which demonstrated an in vivo effect on JNK activity when dosed orally in our kainic acid mouse model as measured by phospho-c-jun reduction.

  DOI：

  10.1016/j.bmcl.2011.01.046
• 作为产物：
  描述：

  5,6,7,8-四氢喹喔啉 在 溴 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 四氢呋喃 、 氯仿 、 乙腈 、 苯 为溶剂， 反应 24.0h， 生成 5-溴喹喔啉
  参考文献：
  名称：

  喹喔啉及其衍生物的溴化：一些新的溴化喹喔啉的有效合成

  摘要：

  研究了几种不同的溴化策略，从几种喹喔啉开始合成溴代喹喔啉衍生物。首先，随着一些已知化合物的替代和有效合成的发展，完成了一些溴化喹喔啉的合成。还开发了一种新颖，清洁，有效的合成方法，用于将喹喔啉选择性还原为1,2,3,4-四氢喹喔啉。所获得的产物通过NMR光谱，元素分析和质谱来表征。

  DOI：

  10.1016/j.tet.2017.02.014

文献信息

• Bromination of Isoquinoline, Quinoline, Quinazoline and Quinoxaline in Strong Acid
  作者：Alex Gouliaev、William Brown

  DOI：10.1055/s-2002-19314

  日期：——

  Bromination of benzazines and benzodiazines most often gives a mixture of products. In this paper, we show that isoquinoline (1) may be regioselectively monobrominated in concentrated H2SO4 using NBS or in CF3SO3H using N,N’-dibromoisocyanuric acid (DBI) to give 5-bromoisoquinoline (2). The bromination was found to be highly sensitive to the choice of brominating agent, acid, temperature and concentration. Quinoline, quinazoline and quinoxaline may be brominated likewise, although with the strong regioselectivity reserved to isoquinoline.

  苯并吡嗪和苯并二嗪的溴化反应通常得到多种产物混合物。本文中，我们展示了异喹啉（1）可在浓硫酸中使用NBS或在三氟甲磺酸中使用N,N’-二溴异氰尿酸（DBI）进行区域选择性单溴化，得到5-溴异喹啉（2）。研究发现，溴化反应对溴化剂、酸、温度和浓度的选择非常敏感。喹啉、喹唑啉和喹喔啉亦可进行类似溴化，尽管其区域选择性不如异喹啉强烈。
• [EN] MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS MUSCARINIQUES DE L'ACÉTYLCHOLINE M1
  申请人：PIPELINE THERAPEUTICS INC

  公开号：WO2019241131A1

  公开（公告）日：2019-12-19

  Provided herein are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

  本文提供了作为肌胆碱乙酰胆碱受体M1（mAChR M1）拮抗剂有用的化合物；制备这些化合物的合成方法；包含这些化合物的药物组合物；以及使用这些化合物和组合物治疗与肌胆碱乙酰胆碱受体功能障碍相关的神经和精神疾病的方法。
• 一种基于氮杂苯和蒽酮类结构的有机化合物及其在OLED上的应用
  申请人：江苏三月光电科技有限公司

  公开号：CN110878092A

  公开（公告）日：2020-03-13

  本发明涉及一种基于氮杂苯和蒽酮类结构的有机化合物及其在OLED器件上的应用，本发明化合物结构中同时含有氮杂苯和蒽酮类结构，具有较高的玻璃化温度和分子热稳定性；在可见光领域吸收低、折射率高，在应用于OLED器件的CPL层后，可有效提升OLED器件的光取出效率；本发明化合物还具有深的HOMO能级和高的电子迁移率，可作为OLED器件的空穴阻挡/电子传输层材料，可有效阻挡空穴或能量从发光层传递至电子层一侧，从而提升空穴和电子在发光层的复合效率，进而提升OLED器件的发光效率和使用寿命。
• [EN] INHIBITORS OF JUN N-TERMINAL KINASE<br/>[FR] INHIBITEURS DE L'ENZYME JUN N-TERMINAL KINASE
  申请人：ELAN PHARM INC

  公开号：WO2010091310A1

  公开（公告）日：2010-08-12

  The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula (I): or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.

  本公开提供了具有以下结构的c-Jun N-末端激酶（JNK）抑制剂（I）的结构，或其盐或溶剂化物，其中环A，Ca，Cb，Z，R5，W和Cy在此处定义。本公开还提供了包括本公开化合物的药物组合物，以及制备和使用本公开化合物和组合物的方法，例如在治疗和预防各种疾病，如阿尔茨海默病。
• PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS
  申请人：Janssen Biotech, Inc.

  公开号：US20180170909A1

  公开（公告）日：2018-06-21

  Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 5 , G 1 , and G 2 are defined herein.

  揭示了一种通过调节MALT1来治疗受影响的疾病、综合症、症状和疾病的化合物、组合物和方法。这些化合物由以下式（I）表示：其中R1、R2、R3、R4、R5、R6、R5、G1和G2在此处定义。

表征谱图